Relapsing and Progressive Forms of Multiple Sclerosis: Insights from Pathology

Overview

Journal Curr Opin Neurol

Specialty Neurology

Date 2014 Apr 12

PMID 24722325

Citations 110

Authors

Ranjan Dutta

Bruce D Trapp

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: The predominant clinical disease course of multiple sclerosis starts with reversible episodes of neurological disability, which transforms into progressive neurological decline. This review provides insight into the pathological differences during relapsing and progressive phases of multiple sclerosis.

Recent Findings: The clinical course of multiple sclerosis is variable, and the disease can be classified into relapsing and progressive phases. Pathological studies have been successful in distinguishing between these two forms of the disease and correlate with the clinical findings in terms of cellular responses, the inflammatory environment, and the location of lesions.

Summary: Available therapies for multiple sclerosis patients, while effective during the relapsing phase, have little benefit for progressive multiple sclerosis patients. Development of therapies to benefit progressive multiple sclerosis patients will require a better understanding of the pathogenesis of progressive multiple sclerosis. This review discusses and compares the pathological findings in relapsing and progressive multiple sclerosis patients.

Citing Articles

Intrinsic retinoic acid synthesis is required for oligodendrocyte progenitor expansion during CNS remyelination.

Nanescu S, Wathieu N, Rosko L, Cha D, Kumar M, Olszewski R Front Cell Neurosci. 2025; 19:1550139.

PMID: 40065911 PMC: 11891161. DOI: 10.3389/fncel.2025.1550139.

Circulating cell-free DNA methylation profiles as noninvasive multiple sclerosis biomarkers: A proof-of-concept study.

Fu H, Huang K, Zhu W, Zhang L, Bandaru R, Wang L medRxiv. 2025; .

PMID: 40034794 PMC: 11875267. DOI: 10.1101/2025.02.14.25322180.

Nrf2 activators for the treatment of rare iron overload diseases: From bench to bedside.

Dong Y, Zheng M, Ding W, Guan H, Xiao J, Li F Redox Biol. 2025; 81:103551.

PMID: 39965404 PMC: 11876910. DOI: 10.1016/j.redox.2025.103551.

Inequities in the Use of Disease-Modifying Therapy Among Adults Living With Multiple Sclerosis in Urban and Rural Areas in Alberta, Canada.

Balcom E, Mccombe J, Kate M, Vu K, Martins K, Aponte-Hao S Neurology. 2025; 104(3):e210251.

PMID: 39772662 PMC: 11708828. DOI: 10.1212/WNL.0000000000210251.

A Clinical Care Algorithm for Detecting Progression in Multiple Sclerosis: RetratEMos Project.

Meca-Lallana J, Robles R, Landete L, Tellez N, Garcia-Dominguez J, Garces P Cureus. 2024; 16(11):e74001.

PMID: 39703306 PMC: 11657311. DOI: 10.7759/cureus.74001.

References

Yin X, Crawford T, Griffin J, Tu P, Lee V, Li C . Myelin-associated glycoprotein is a myelin signal that modulates the caliber of myelinated axons. J Neurosci. 1998; 18(6):1953-62. PMC: 6792914. View

Mahad D, Ziabreva I, Lassmann H, Turnbull D . Mitochondrial defects in acute multiple sclerosis lesions. Brain. 2008; 131(Pt 7):1722-35. PMC: 2442422. DOI: 10.1093/brain/awn105. View

Franklin R, ffrench-Constant C, Edgar J, Smith K . Neuroprotection and repair in multiple sclerosis. Nat Rev Neurol. 2012; 8(11):624-34. DOI: 10.1038/nrneurol.2012.200. View

Chang A, Staugaitis S, Dutta R, Batt C, Easley K, Chomyk A . Cortical remyelination: a new target for repair therapies in multiple sclerosis. Ann Neurol. 2012; 72(6):918-26. PMC: 3535551. DOI: 10.1002/ana.23693. View

Kutzelnigg A, Lucchinetti C, Stadelmann C, Bruck W, Rauschka H, Bergmann M . Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain. 2005; 128(Pt 11):2705-12. DOI: 10.1093/brain/awh641. View

Bruck W, Lucchinetti C, Lassmann H . The pathology of primary progressive multiple sclerosis. Mult Scler. 2002; 8(2):93-7. DOI: 10.1191/1352458502ms785rr. View

Dutta R, McDonough J, Yin X, Peterson J, Chang A, Torres T . Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients. Ann Neurol. 2006; 59(3):478-89. DOI: 10.1002/ana.20736. View

Skulina C, Schmidt S, Dornmair K, Babbe H, Roers A, Rajewsky K . Multiple sclerosis: brain-infiltrating CD8+ T cells persist as clonal expansions in the cerebrospinal fluid and blood. Proc Natl Acad Sci U S A. 2004; 101(8):2428-33. PMC: 356967. DOI: 10.1073/pnas.0308689100. View

Kornek B, Storch M, Bauer J, Djamshidian A, Weissert R, Wallstroem E . Distribution of a calcium channel subunit in dystrophic axons in multiple sclerosis and experimental autoimmune encephalomyelitis. Brain. 2001; 124(Pt 6):1114-24. DOI: 10.1093/brain/124.6.1114. View

10.

Narayana P . Magnetic resonance spectroscopy in the monitoring of multiple sclerosis. J Neuroimaging. 2005; 15(4 Suppl):46S-57S. PMC: 1351238. DOI: 10.1177/1051228405284200. View

11.

Huseby E, Liggitt D, Brabb T, Schnabel B, Ohlen C, Goverman J . A pathogenic role for myelin-specific CD8(+) T cells in a model for multiple sclerosis. J Exp Med. 2001; 194(5):669-76. PMC: 2195947. DOI: 10.1084/jem.194.5.669. View

12.

Geurts J, Calabrese M, Fisher E, Rudick R . Measurement and clinical effect of grey matter pathology in multiple sclerosis. Lancet Neurol. 2012; 11(12):1082-92. DOI: 10.1016/S1474-4422(12)70230-2. View

13.

Weiner H . The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease?. Ann Neurol. 2009; 65(3):239-48. DOI: 10.1002/ana.21640. View

14.

Napoli S, Bakshi R . Magnetic resonance imaging in multiple sclerosis. Rev Neurol Dis. 2006; 2(3):109-16. View

15.

Peterson J, Bo L, Mork S, Chang A, Trapp B . Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol. 2001; 50(3):389-400. DOI: 10.1002/ana.1123. View

16.

Hauser S, Oksenberg J . The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration. Neuron. 2006; 52(1):61-76. DOI: 10.1016/j.neuron.2006.09.011. View

17.

Bo L, Vedeler C, Nyland H, Trapp B, Mork S . Intracortical multiple sclerosis lesions are not associated with increased lymphocyte infiltration. Mult Scler. 2003; 9(4):323-31. DOI: 10.1191/1352458503ms917oa. View

18.

Lassmann H, van Horssen J, Mahad D . Progressive multiple sclerosis: pathology and pathogenesis. Nat Rev Neurol. 2012; 8(11):647-56. DOI: 10.1038/nrneurol.2012.168. View

19.

Matute C, Domercq M, Sanchez-Gomez M . Glutamate-mediated glial injury: mechanisms and clinical importance. Glia. 2005; 53(2):212-24. DOI: 10.1002/glia.20275. View

20.

Popescu B, Lucchinetti C . Meningeal and cortical grey matter pathology in multiple sclerosis. BMC Neurol. 2012; 12:11. PMC: 3315403. DOI: 10.1186/1471-2377-12-11. View